Medical - Care Facilities
Compare Stocks
2 / 10Stock Comparison
CYH vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
CYH vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology |
| Market Cap | $404M | $1721.78T |
| Revenue (TTM) | $21.48B | $0.00 |
| Net Income (TTM) | $-88M | $-168M |
| Gross Margin | 53.7% | — |
| Operating Margin | -39.8% | — |
| Forward P/E | 0.8x | — |
| Total Debt | $11.58B | $22M |
| Cash & Equiv. | $260M | $194M |
CYH vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Community Health Sy… (CYH) | 100 | 91.1 | -8.9% |
| DBV Technologies S.… (DBVT) | 100 | 41.4 | -58.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CYH vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CYH is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 2 yrs, beta 1.60
- Rev growth -1.2%, EPS growth 196.7%, 3Y rev CAGR 0.7%
- -80.7% 10Y total return vs DBVT's -86.8%
DBVT carries the broadest edge in this set and is the clearest fit for sleep-well-at-night and defensive.
- Lower volatility, beta 1.26, Low D/E 12.8%, current ratio 3.67x
- Beta 1.26, current ratio 3.67x
- 0.3% margin vs CYH's -0.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -1.2% revenue growth vs DBVT's -100.0% | |
| Quality / Margins | 0.3% margin vs CYH's -0.4% | |
| Stability / Safety | Beta 1.26 vs CYH's 1.60 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +114.1% vs CYH's -1.0% | |
| Efficiency (ROA) | -0.7% ROA vs DBVT's -89.0% |
CYH vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
CYH vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CYH and DBVT operate at a comparable scale, with $21.5B and $0 in trailing revenue.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $21.5B | $0 |
| EBITDAEarnings before interest/tax | -$7.8B | -$112M |
| Net IncomeAfter-tax profit | -$88M | -$168M |
| Free Cash FlowCash after capex | -$200M | -$151M |
| Gross MarginGross profit ÷ Revenue | +53.7% | — |
| Operating MarginEBIT ÷ Revenue | -39.8% | — |
| Net MarginNet income ÷ Revenue | -0.4% | — |
| FCF MarginFCF ÷ Revenue | -0.9% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -45.2% | +91.5% |
Valuation Metrics
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $404M | $1721.78T |
| Enterprise ValueMkt cap + debt − cash | $11.7B | $1721.78T |
| Trailing P/EPrice ÷ TTM EPS | 0.76x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.03x | — |
| Price / BookPrice ÷ Book value/share | — | 0.66x |
| Price / FCFMarket cap ÷ FCF | 1.94x | — |
Profitability & Efficiency
CYH leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), CYH scores 6/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | — | -130.2% |
| ROA (TTM)Return on assets | -0.7% | -89.0% |
| ROICReturn on invested capital | -70.1% | — |
| ROCEReturn on capital employed | -87.3% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | — | 0.13x |
| Net DebtTotal debt minus cash | $11.3B | -$172M |
| Cash & Equiv.Liquid assets | $260M | $194M |
| Total DebtShort + long-term debt | $11.6B | $22M |
| Interest CoverageEBIT ÷ Interest expense | 4.89x | -189.82x |
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,344 today (with dividends reinvested), compared to $2,049 for CYH. Over the past 12 months, DBVT leads with a +114.1% total return vs CYH's -1.0%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.4% vs CYH's -6.2% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -7.4% | +5.5% |
| 1-Year ReturnPast 12 months | -1.0% | +114.1% |
| 3-Year ReturnCumulative with dividends | -17.5% | +20.4% |
| 5-Year ReturnCumulative with dividends | -79.5% | -66.6% |
| 10-Year ReturnCumulative with dividends | -80.7% | -86.8% |
| CAGR (3Y)Annualised 3-year return | -6.2% | +6.4% |
Risk & Volatility
DBVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than CYH's 1.60 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.8% from its 52-week high vs CYH's 64.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.60x | 1.26x |
| 52-Week HighHighest price in past year | $4.47 | $26.18 |
| 52-Week LowLowest price in past year | $2.38 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +64.2% | +76.8% |
| RSI (14)Momentum oscillator 0–100 | 44.0 | 43.8 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 253K |
Analyst Outlook
CYH leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates CYH as "Hold" and DBVT as "Buy". Consensus price targets imply 130.5% upside for DBVT (target: $46) vs 2.1% for CYH (target: $3).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $2.93 | $46.33 |
| # AnalystsCovering analysts | 37 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 2 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.5% | 0.0% |
DBVT leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). CYH leads in 2 (Profitability & Efficiency, Analyst Outlook).
CYH vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CYH or DBVT a better buy right now?
Community Health Systems, Inc.
(CYH) offers the better valuation at 0. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CYH or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -66. 6%, compared to -79. 5% for Community Health Systems, Inc. (CYH). Over 10 years, the gap is even starker: CYH returned -80. 7% versus DBVT's -86. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CYH or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Community Health Systems, Inc. 's 1. 60β — meaning CYH is approximately 27% more volatile than DBVT relative to the S&P 500.
04Which is growing faster — CYH or DBVT?
On earnings-per-share growth, the picture is similar: Community Health Systems, Inc.
grew EPS 196. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CYH or DBVT?
Community Health Systems, Inc.
(CYH) is the more profitable company, earning 4. 1% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 4. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -79. 4% for CYH. At the gross margin level — before operating expenses — CYH leads at 8. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CYH or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CYH or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DBV Technologies S.
A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Community Health Systems, Inc. (CYH) carries a higher beta of 1. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DBVT: -86. 8%, CYH: -80. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CYH and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CYH is a small-cap deep-value stock; DBVT is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.